Results 11 to 20 of about 11,283,677 (180)

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial. [PDF]

Transplant Cell Ther, 2022
Perales MA, Kuruvilla J, Snider JT, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel AR, Johnston PB.   +8 more
europepmc   +2 more sources

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Journal of Clinical Oncology, 2022
PURPOSE Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study
Michael Wang, J. Muñoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. Mcsweeney, D. Miklos, J. Pagel, M. Kersten, K. Bouabdallah, R. Khanal, M. Topp, R. Houot, A. Beitinjaneh, W. Peng, X. Fang, R. Shen, R. Siddiqi, I. Kloos, P. Reagan   +24 more
semanticscholar   +1 more source

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood, 2023
Key Points • Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory LBCL.• Durable responses were associated with expansion of chimeric antigen receptor T cells early after intravenous infusion.
S. Neelapu, C. Jacobson, A. Ghobadi, D. Miklos, L. Lekakis, O. Oluwole, Yi-Chung Lin, I. Braunschweig, B. Hill, J. Timmerman, A. Deol, P. Reagan, P. Stiff, I. Flinn, U. Farooq, A. Goy, P. Mcsweeney, J. Muñoz, T. Siddiqi, J. Chavez, A. Herrera, N. Bartlett, Adrian Bot, R. Shen, Jinghui Dong, Kanwarjit Singh, H. Miao, Jenny J. Kim, Yan Zheng, F. Locke   +29 more
semanticscholar   +1 more source

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

Blood, 2021
ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-ALL. We report the phase 1 results.
B. Shah, M. Bishop, O. Oluwole, A. Logan, M. Baer, W. Donnellan, K. O'Dwyer, H. Holmes, M. Arellano, A. Ghobadi, J. Pagel, Yi Lin, R. Cassaday, Jae H. Park, M. Abedi, J. Castro, D. DeAngelo, Adriana K Malone, R. Mawad, G. Schiller, J. Rossi, A. Bot, T. Shen, L. Goyal, R. Jain, R. Vezan, W. Wierda   +26 more
semanticscholar   +1 more source

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Nature Medicine, 2022
High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study (ClinicalTrials.gov NCT03761056) we evaluated axicabtagene ciloleucel (axi-cel), an autologous ...
S. Neelapu, M. Dickinson, J. Muñoz, M. Ulrickson, C. Thieblemont, O. Oluwole, A. Herrera, C. Ujjani, Yi Lin, P. Riedell, N. Kekre, S. de Vos, C. Lui, Francesca Milletti, Jinghui Dong, Hai-rong Xu, J. Chavez   +16 more
semanticscholar   +1 more source

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Blood, 2023
Key Points • Axi-cel demonstrated durable responses in patients with FL and MZL after 3 years of follow-up.• Elevated baseline total metabolic tumor volume and recent prior bendamustine use may affect durable remissions of patients with FL.
S. Neelapu, J. Chavez, A. Sehgal, N. Epperla, M. Ulrickson, E. Bachy, Pashna N. Munshi, C. Casulo, David G. Maloney, S. de Vos, Ran Reshef, Lori A. Leslie, O. Oluwole, Ibrahim Yakoubagha, R. Khanal, Joseph D. Rosenblatt, Ronald Korn, Weixing Peng, C. Lui, Jacob Wullf, Rhine R Shen, S. Poddar, A. S. Jung, H. Miao, S. Beygi, C. Jacobson   +25 more
semanticscholar   +1 more source

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Journal of Hematology & Oncology, 2022
Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results.
B. Shah, A. Ghobadi, O. Oluwole, A. Logan, N. Boissel, R. Cassaday, T. Leguay, M. Bishop, M. Topp, D. Tzachanis, K. O'Dwyer, M. Arellano, Yi-Chung Lin, M. Baer, G. Schiller, Jae H. Park, M. Subklewe, M. Abedi, M. Minnema, W. Wierda, D. DeAngelo, P. Stiff, D. Jeyakumar, Jinghui Dong, S. Adhikary, Lang Zhou, P. Schuberth, Imi Faghmous, B. K. Masouleh, R. Houot   +29 more
semanticscholar   +1 more source

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Journal for ImmunoTherapy of Cancer, 2023
Background Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European ...
B. Shah, R. Cassaday, Jae H. Park, R. Houot, O. Oluwole, A. Logan, N. Boissel, T. Leguay, M. Bishop, M. Topp, D. Tzachanis, K. O'Dwyer, M. Arellano, Yi-Chung Lin, M. Baer, G. Schiller, M. Subklewe, M. Abedi, M. Minnema, W. Wierda, D. DeAngelo, P. Stiff, D. Jeyakumar, Daqin Mao, S. Adhikary, Lang Zhou, P. Schuberth, Rita Damico Khalid, Armin Ghobadia   +28 more
semanticscholar   +1 more source

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Blood, 2022
Key Points • Axi-cel showed clinically meaningful improvements in QoL in 2L LBCL over SOC at days 100 and 150.• There was a trend toward faster recovery to baseline QoL in patients who received axi-cel.
M. Elsawy, J. Chavez, I. Avivi, J. Larouche, L. Wannesson, Kate Cwynarski, Keren Osman, K. Davison, J. Rudzki, S. Dahiya, K. Dorritie, S. Jaglowski, J. Radford, F. Morschhauser, D. Cunningham, A. M. Martin Garcia-Sancho, D. Tzachanis, M. Ulrickson, R. Karmali, N. Kekre, C. Thieblemont, G. Enblad, P. Dreger, R. Malladi, N. Joshi, Wei-Jhih Wang, C. Solem, J. Snider, P. Cheng, C. To, M. Kersten   +30 more
semanticscholar   +1 more source

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Blood, 2022
As yet, there are no randomized studies of chimeric antigen receptor (CAR) T-cell therapy versus standard therapy in patients with multiple relapsed follicular lymphoma.
P. Ghione, M. Palomba, Anik R Patel, S. Bobillo, K. Deighton, C. Jacobson, Myrna R Nahas, A. Hatswell, A. S. Jung, S. Kanters, J. Snider, S. Neelapu, Maria Teresa Ribeiro, M. Brookhart, H. Ghesquières, J. Radford, J. Gribben   +16 more
semanticscholar   +1 more source